Kluska Magdalena, Piastowska-Ciesielska Agnieszka Wanda, Tokarz Paulina
Department of Molecular Genetics, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Department of Cell Cultures and Genomic Analysis, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.
Curr Issues Mol Biol. 2023 Jul 29;45(8):6325-6338. doi: 10.3390/cimb45080399.
Cancer cells are characterised by uncontrolled cell proliferation; however, some of them can temporarily arrest their cell cycle at the G0 or G1 phase, which could contribute to tumour heterogeneity and drug resistance. The cell cycle status plays a critical role in chemosensitivity; however, the influence of G0- and G1-arrest has not been elucidated. To study the cell cycle arrest-mediated resistance, we used MCF-7 cells and generated three populations of cells: (1) cells arrested in the G0-like phase, (2) cells that resumed the cell cycle after the G0-like phase and (3) cells arrested in early G1 with a history of G0-like arrest. We observed that both the G0-like- and the G1-arrested cells acquired resistance to apoptosis induced by oxidative stress, accompanied by a decreased intracellular reactive oxygen species and DNA damage. This effect was associated with increased autophagy, likely facilitating their survival at DNA damage insult. The cell cycle reinitiation restored a sensitivity to oxidative stress typical for cells with a non-modulated cell cycle, with a concomitant decrease in autophagy. Our results support the need for further research on the resistance of G0- and G1-arrested cancer cells to DNA-damaging agents and present autophagy as a candidate for targeting in anticancer treatment.
癌细胞的特征是细胞增殖不受控制;然而,其中一些细胞可以在G0或G1期暂时阻滞其细胞周期,这可能导致肿瘤异质性和耐药性。细胞周期状态在化学敏感性中起关键作用;然而,G0期和G1期阻滞的影响尚未阐明。为了研究细胞周期阻滞介导的耐药性,我们使用MCF-7细胞并产生了三类细胞群体:(1) 阻滞在类G0期的细胞,(2) 在类G0期后恢复细胞周期的细胞,以及(3) 有类G0期阻滞历史且阻滞在早期G1期的细胞。我们观察到,类G0期和G1期阻滞的细胞均获得了对氧化应激诱导的细胞凋亡的抗性,同时细胞内活性氧种类和DNA损伤减少。这种效应与自噬增加有关,可能有助于它们在DNA损伤刺激下存活。细胞周期重新启动恢复了对具有未调节细胞周期的细胞典型的氧化应激的敏感性,同时自噬减少。我们的结果支持对G0期和G1期阻滞的癌细胞对DNA损伤剂的抗性进行进一步研究的必要性,并提出自噬作为抗癌治疗中的一个靶向候选对象。